Results 11 to 20 of about 5,099,009 (221)
Haematologica, 2009 This perspective article by Drs. Pileri and Falini examines the diagnosis and bio-pathology of mantle cell lymphoma in the light of the criteria of the WHO Classification and recent reports. See related articles on pages 1555, 1563 and 1595.
Stefano A. Pileri, Brunangelo Falini
doaj +3 more sources
Case Report: Occult mantle cell lymphoma in a synchronous rectal collision tumor with adenocarcinoma: retrospective reclassification and multispecimen molecular profiling [PDF]
Frontiers in OncologyCollision tumors composed of colorectal adenocarcinoma and mantle cell lymphoma are exceptionally rare, and component-resolved molecular characterization is largely lacking. We report a 65-year-old woman who initially presented with rectal adenocarcinoma
Qing Zhang +3 more
doaj +2 more sources
Polish Journal of Pathology, 2017 Multiple primary neoplasms may also occur synchronously. Lymphoma may coexist with second malignant tumor in its primary location or malignant tumor may metastases to lymphomatous lymph nodes.
Anna Szumera-Ciećkiewicz +2 more
doaj +2 more sources
Primary gastric mantle cell lymphoma [PDF]
Hematology Reports, 2012 Mantle cell lymphoma represents 2,5-7% all of non Hodgkin’s lymphomas. Stomach is the most common site of extranodal lymphoma. However, that is not the case with mantle cell lymphoma, which is extremely rare.
Duska Petranovic +7 more
doaj +5 more sources
Haematologica, 2011 Mantle cell lymphoma (MCL) accounts for approximately 6% of all non-Hodgkin’s lymphomas[1][1] and is characterized by the over-expression of cyclin D1 with cell cycle dysregulation, secondary to the genetic abnormality t(11;14)(q13;q32).[2][2] It often has an aggressive clinical course and ...
Michelle Furtado, Simon Rule
doaj +3 more sources
Smoldering mantle cell lymphoma [PDF]
Journal of Experimental & Clinical Cancer Research, 2017 Background Mantle cell lymphoma (MCL) is an aggressive disease, with poor prognosis and a limited survival. However, some patients with indolent MCL can survive beyond 7~10 years. These patients remain largely asymptomatic and can be in observation for a
Haige Ye +6 more
doaj +3 more sources
Factores pronósticos biológicos y clínicos en el linfoma de células del manto [PDF]
, 2008 [spa] El linfoma de células del manto (LCM) es una entidad heterogénea tanto en sus aspectos biológicos como en su comportamiento clínico. La existencia de pacientes con mala respuesta al tratamiento sugiere que, de manera análoga a otros síndromes ...
Ferrer del Álamo, Ana
core +6 more sources
Case report: Composite mantle cell lymphoma and classical Hodgkin lymphoma
Pathology and Oncology Research, 2023 Composite mantle cell lymphoma and classical Hodgkin lymphoma is very rare and the actual origin of it is still unclear. Here we reported a new case of composite mantle cell lymphoma and classical Hodgkin lymphoma and analyzed its molecular changes ...
Hongyu Wang +4 more
doaj +1 more source
Hematology/Oncology and Stem Cell Therapy, 2023 Mantle cell lymphoma is a rare subtype of non-Hodgkin’s lymphoma with poor prognosis and continue to be challenging to treat. The choice of first line induction regimen remains a topic of debate due paucity of clinical trials.
Omar Albanyan +9 more
doaj +1 more source
The potential therapeutic role of selenium in diffuse large B-cell lymphoma [PDF]
, 2011 PhDThe clinical background to this work confirms the very poor outcome of patients with recurrent diffuse large B-cell lymphoma (DLBCL) and highlights the need for better therapies.
Kassam, Shireen
core +4 more sources